Biotech firms like Axsome and BioNTech develop innovative treatments, offering growth potential for investors. Strong financial positions reduce risk in biotech investing, prioritizing firms with ...

On the other hand, if a biotech company gets a new drug sanctioned by the FDA and the demand is high, the stock value can double or even triple overnight. An online broker can help you trade ...

True, this mid-cap biotech still looks risky. It has yet to start late-stage studies for any candidate. And like most clinical-stage biotechs, Viking generates no revenue and is unprofitable.